Related Experiment Video
Updated: Sep 21, 2025
Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma
Anne S Boewe1, Silke Wemmert2, Philipp Kulas2
1Institute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Germany.
Abstract:
Juvenile angiofibroma (JA) is a rare fibrovascular neoplasm predominately found within the posterior nasal cavity of adolescent males. JA expresses the proteoglycan nerve-glial antigen (NG)2, which crucially determines the migratory capacity of distinct cancer cells. Moreover, it is known that the protein kinase CK2 regulates NG2 gene expression. Therefore, in the present study, we analyzed whether the inhibition of CK2 suppresses NG2-dependent JA cell proliferation and migration. For this purpose, we assessed the expression of NG2 and CK2 in patient-derived JA tissue samples, as well as in patient-derived JA cell cultures by Western blot, immunohistochemistry, flow cytometry and quantitative real-time PCR. The mitochondrial activity, proliferation and migratory capacity of the JA cells were determined by water-soluble tetrazolium (WST)-1, 5-bromo-2'-deoxyuridine (BrdU) and collagen sprouting assays. We found that NG2 and CK2 were expressed in both the JA tissue samples and cell cultures. The treatment of the JA cells with the two CK2 inhibitors, CX-4945 and SGC-CK2-1, significantly reduced NG2 gene and protein expression when compared to the vehicle-treated cells. In addition, the loss of CK2 activity suppressed the JA cell proliferation and migration. These findings indicate that the inhibition of CK2 may represent a promising therapeutic approach for the treatment of NG2-expressing JA.
Insights
Juvenile angiofibroma (JA) is a rare cancer where inhibiting protein kinase CK2 reduces nerve-glial antigen 2 (NG2) expression. This suppression effectively decreases JA cell proliferation and migration, suggesting a potential new therapy.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Juvenile angiofibroma (JA) is a rare fibrovascular neoplasm primarily affecting adolescent males, characterized by expression of nerve-glial antigen 2 (NG2).
- NG2 expression is linked to cancer cell migration, and protein kinase CK2 (CK2) is known to regulate NG2 gene expression.
- Understanding the interplay between CK2 and NG2 in JA is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate whether inhibiting CK2 can suppress NG2-dependent proliferation and migration in juvenile angiofibroma cells.
- To analyze the expression of NG2 and CK2 in patient-derived JA tissues and cell cultures.
- To evaluate the therapeutic potential of CK2 inhibitors in treating JA.
Main Methods:
- Western blot, immunohistochemistry, flow cytometry, and quantitative real-time PCR were used to assess NG2 and CK2 expression.
- Cellular assays including WST-1, BrdU, and collagen sprouting were employed to measure mitochondrial activity, proliferation, and migration.
- Patient-derived JA tissue samples and cell cultures were utilized for experimental analysis.
Main Results:
- Both NG2 and CK2 were confirmed to be expressed in JA tissues and cell cultures.
- Treatment with CK2 inhibitors (CX-4945 and SGC-CK2-1) significantly reduced NG2 gene and protein expression in JA cells.
- Inhibition of CK2 activity led to suppressed JA cell proliferation and migration.
Conclusions:
- CK2 plays a significant role in regulating NG2 expression in juvenile angiofibroma.
- Inhibiting CK2 effectively reduces JA cell proliferation and migration, highlighting its potential therapeutic value.
- Targeting CK2 represents a promising therapeutic strategy for NG2-expressing juvenile angiofibroma.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis